This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 2001;286:40.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

MMWR. 2001;50:470

In April 2001, Pharmacia Corporation (Peapack, New Jersey) announced it was discontinuing U.S. production of spectinomycin (Trobicin®)* because of low sales volume; remaining spectinomycin inventory will expire on June 30, 2001. No other pharmaceutical company manufactures or sells spectinomycin in the United States.

CDC recommends treating patients infected with Neisseria gonorrhoeae who have contraindications to cephalosporins and fluoroquinolones with spectinomycin.¹ Patients in this category include: (1) pregnant women with documented cephalosporin allergies (fluoroquinolones are contraindicated in pregnancy); and (2) patients with documented cephalosporin allergies who acquired gonorrhea infection in areas where fluoroquinolone-resistant N. gonorrhoeae is endemic (e.g., Asia, Hawaii, and other Pacific Islands).²

For access to spectinomycin until June 30, contact Wendy Johnson, Pharmacia Corporation, telephone (800) 976-7741, ext. 30110 or fax (800) 852-6421. In response to this shortage, CDC and the Food and Drug Administration are working with Pharmacia Corporation to identify a solution. Interim alternative treatment . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

U.S. Centers for Disease Control and Prevention Guidelines for the Treatment of Sexually Transmitted Diseases: An Opportunity To Unify Clinical and Public Health Practice
Workowski et al.
ANN INTERN MED 2002;137:255-262.
ABSTRACT | FULL TEXT